VX-445/TEZ/IVA Triple Combination Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function CFTR Mutation
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Expanded access; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 16 Aug 2019 New trial record